A Phase 2 interventional study of Mycophenolate Mofetil and Placebo in Systemic Sclerosis With Lung Involvement, Systemic Sclerosis and Interstitial Lung Disease, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Scleroderma, Systemic with a site in Canada — 12 open to participants now, 13 under way, 4 of them phase 3. Scleroderma, Systemic · Canada.
Among the 44 studies in Scleroderma, Systemic with a site in Canada, this one is the 30th largest by planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 1 of the 12 other live ones, and was the 34th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →12 of the 44 studies in Scleroderma, Systemic with a site in Canada are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Canada, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in Canada, United States, Argentina and 42 more countries
Ages 18+
Allogene Therapeutics · Sites in Canada, United States
Ages 18–74
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Primus Pharmaceuticals · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 10
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is close to the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 115 across the 39 interventional studies, 63 across the 5 observational. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 44 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
4 of the studies in Scleroderma, Systemic with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT05785065Centre hospitalier de l'Université de Montréal (CHUM)Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease | 2026-12 |
| NCT04356287Marie Hudson, MDTreatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis | 2026-12 |
| NCT06256575Primus PharmaceuticalsStudy of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis | 2027-07-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies in Scleroderma, Systemic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement. Participants will be recruited over 12 months at 3 academic centers and assigned randomly to receive either mycophenolate mofetil or placebo, a look-alike substance that contains no active drug, for 96 weeks.
Background: Systemic sclerosis (SSc, scleroderma) is a rare but life-threatening systemic autoimmune disease characterized by microvasculopathy, serum autoantibodies, inflammation and fibrosis of the skin and internal organs. Early rapidly progressive SSc remains the most lethal autoimmune rheumatic disease, with over 60% mortality at 5 years in high-risk patients. Interstitial lung disease (ILD) is the leading cause of SSc-related mortality and affects over half of SSc patients. SSc-ILD is currently treated with immunosuppressive and anti-fibrotic drugs, with the first-line treatment being mycophenolate mofetil (MMF), although treatments have modest benefits when initiated in advanced stages of disease. Emerging data suggest that earlier treatment, when lung function is still normal despite evidence of ILD on computed tomography scan ("subclinical SSc-ILD"), may lead to improved outcomes, suggesting a window of treatment opportunity.
Research Aims: The goal of the proposed pilot RCT is to establish the feasibility of a phase III RCT that will assess the efficacy of MMF in subclinical SSc-ILD. Specifically, we aim to:
Methods: Participants will be adults with SSc, ILD diagnosed within the past 3 years and a normal forced vital capacity (≥ 80%). Participants will be recruited over 12 months at 3 academic centers affiliated to the Canadian Scleroderma Research Group. Eligible participants will be assigned using stratified randomization to receive either MMF (up to 2 grams daily) or placebo for 96 weeks. The primary feasibility outcome will be the rate of recruitment per site over 12 months. A Bayesian approach will be used to estimate the probability of reaching the target sample size based on observed recruitment rates, with decision rules to continue, adapt, or stop the trial. Data collected on the primary clinical efficacy outcome (annual rate of decline in forced vital capacity over 96 weeks) will be used to inform the analysis of the phase III trial (as an informative prior) through a Bayesian inference framework.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of medications with putative lung disease-modifying properties:
Any to MMF, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 to 4 capsules of mycophenolate mofetil twice daily.
Drug: Mycophenolate Mofetil
2 to 4 capsules of placebo twice daily.
Other: Placebo
The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks. The dose scheduling will be as follow: Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day
The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks. The dose scheduling will be as follow: Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day
Total number of potentially eligible patients identified per site
Time frame: Over one year
Proportion of potentially eligible patients who provide consent per site
Time frame: Over one year
Proportion of consented participants who meet the eligibility criteria per site
Time frame: Over one year
Monthly rate of randomized participants per site
Time frame: Over one year
Adherence to treatment as assessed by Participant Dosing Diaries
Time frame: From the first dose to the last dose taken for each participant, up to 96 weeks
Drug adherence rate as assessed by Pharmacy Accountability Logs
Time frame: From the first dose to the last dose taken for each participant, up to 96 weeks
Adherence to the study protocol as assessed by the number of protocol deviations
Time frame: Over total study period (up to 96 weeks per participant)
Proportion of participants intolerant to the study drug who discontinue trial treatment
Time frame: Over total study period (up to 96 weeks per participant)
Proportion of participants receiving the allocated treatment at 48 weeks
Time frame: At 48 weeks
Proportion of participants receiving the allocated treatment at 96 weeks
Time frame: At 96 weeks
Proportion of participants with complete primary efficacy outcome data at 48 weeks
Time frame: At 48 weeks
Proportion of participants with complete primary efficacy outcome data at 96 weeks
Time frame: At 96 weeks
Proportion of participants lost to follow-up
Time frame: Over total study period (up to 96 weeks per participant)
Frequency of treatment-related adverse events
Incidence and severity of AEs, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
Time frame: Over total study period (up to 96 weeks per participant)
Annual rate of decline in percent (%) predicted forced vital capacity (FVC) over 48 weeks
Time frame: Over 48 weeks
Annual rate of decline in percent (%) predicted forced vital capacity (FVC) over 96 weeks
Time frame: Over 96 weeks
Proportion of participants having clinically meaningful progression
Clinically meaningful progression defined by the Outcome Measures in Rheumatology (OMERACT) for connective tissue disease-associated interstitial lung diseases (CTD-ILD) (defined as a ≥10% relative decline in FVC from baseline, or a ≥5% to \<10% relative decline in FVC associated with a ≥15% relative decline in diffusion capacity \[DLCO\])
Time frame: Over total study period (up to 96 weeks per participant)
Time to clinically meaningful progression
Clinically meaningful progression as defined by Outcome Measures in Rheumatology (OMERACT) for connective tissue disease- associated interstitial lung diseases (CTD-ILD) (defined as a ≥10% relative decline in FVC from baseline, or a ≥5% to \<10% relative decline in FVC associated with a ≥15% relative decline in diffusion capacity \[DLCO\])
Time frame: Over total study period (up to 96 weeks per participant)
Proportion of participants having an absolute decrease in FVC of at least 3.3% predicted
An absolute decrease in FVC of at least 3.3% predicted was proposed as the minimal clinically important difference estimate for worsening of FVC in patients with SSc-ILD.
Time frame: Over total study period (up to 96 weeks per participant)
Time to an absolute decrease in FVC of at least 3.3% predicted
An absolute decrease in FVC of at least 3.3% predicted was proposed as the minimal clinically important difference estimate for worsening of FVC in patients with SSc-ILD.
Time frame: Over total study period (up to 96 weeks per participant)
Proportion of participants having progressive pulmonary fibrosis
Progressive pulmonary fibrosis defined by 2022 ATS/ERS/JRS/ALAT guidelines
Time frame: Over total study period (up to 96 weeks per participant)
Time to progressive pulmonary fibrosis
Progressive pulmonary fibrosis defined by 2022 ATS/ERS/JRS/ALAT guidelines
Time frame: Over total study period (up to 96 weeks per participant)
Annual rate of decline in percent (%) predicted total lung capacity over 48 weeks
Time frame: Over 48 weeks
Annual rate of decline in percent (%) predicted total lung capacity over 96 weeks
Time frame: Over 96 weeks
Annual rate of decline in percent (%) predicted diffusion capacity for carbon monoxide (DLCO) over 48 weeks
Time frame: Over 48 weeks
Annual rate of decline in percent (%) predicted DLCO over 96 weeks
Time frame: Over 96 weeks
Change from baseline in percent (%) extent of ILD, ground-glass opacities, reticular infiltrates and honeycombing, and in pulmonary vessel volume at 48 weeks
Measured on high-resolution computed tomography chest scan using automated lung texture analysis
Time frame: At 48 weeks
Change from baseline in percent (%) extent of ILD, ground-glass opacities, reticular infiltrates and honeycombing, and in pulmonary vessel volume at 96 weeks
Measured on high-resolution computed tomography chest scan using automated lung texture analysis
Time frame: At 96 weeks
Change from baseline in St-George Respiratory Questionnaire at 48 weeks
Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At 48 weeks
Change from baseline in St-George Respiratory Questionnaire at 96 weeks
Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At 96 weeks
Change from baseline in Leicester Cough Questionnaire at 48 weeks
Scores (total) range from 3 to 21, with higher scores indicating less limitations.
Time frame: At 48 weeks
Change from baseline in Leicester Cough Questionnaire at 96 weeks
Scores (total) range from 3 to 21, with higher scores indicating less limitations.
Time frame: At 96 weeks
Change from baseline in health assessment questionnaire modified for scleroderma at 48 weeks
The SHAQ consists of the Health assessment questionnaire (HAQ) and visual analogue scales for pain, patient global assessment, vascular, digital ulcers, lung involvement and gastrointestinal involvement. Scores range from 0 to 3, with higher scores indicating more limitations.
Time frame: At 48 weeks
Change from baseline in health assessment questionnaire modified for scleroderma at 96 weeks
The SHAQ consists of the Health assessment questionnaire (HAQ) and visual analogue scales for pain, patient global assessment, vascular, digital ulcers, lung involvement and gastrointestinal involvement. Scores range from 0 to 3, with higher scores indicating more limitations.
Time frame: At 96 weeks
Change from baseline in 36-items short form survey (SF-36) at 48 weeks
Eight scales with scores range from 0 to 100, with higher scores indicating less limitations.
Time frame: At 48 weeks
Change from baseline in 36-items short form survey (SF-36) at 96 weeks
Eight scales with scores ranging from 0 to 100, with higher scores indicating less limitations.
Time frame: At 96 weeks
Change from baseline in EuroQoL five dimensions (EQ-5D-5L) at 48 weeks
The EQ-5D-5L questionnaire possesses 5 levels for each of the five dimensions. The five dimensions are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with the following possible five responses: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Scores are converted into an index value ranging from 0 to 1, with higher scores indicating better health state.
Time frame: At 48 weeks
Change from baseline in EuroQoL five dimensions (EQ-5D-5L) at 96 weeks
The EQ-5D-5L questionnaire possesses 5 levels for each of the five dimensions. The five dimensions are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with the following possible five responses: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Scores are converted into an index value ranging from 0 to 1, with higher scores indicating better health state.
Time frame: At 96 weeks
Change from baseline in patient global assessment at 48 weeks
Visual analogue scale from 0 to 10, with higher scores indicating worse disease.
Time frame: At 48 weeks
Change from baseline in patient global assessment at 96 weeks
Visual analogue scale from 0 to 10, with higher scores indicating worse disease.
Time frame: At 96 weeks
Change from baseline in physician global assessment at 48 weeks
Visual analogue scale from 0 to 10, with higher scores indicating worse disease.
Time frame: At 48 weeks
Change from baseline in physician global assessment at 96 weeks
Visual analogue scale from 0 to 10, with higher scores indicating worse disease.
Time frame: At 96 weeks
Change from baseline in 6-minute walk oxygen saturation at 48 weeks
Oxygen saturation at nadir during the 6-minute walk test
Time frame: At 48 weeks
Change from baseline in 6-minute walk oxygen desaturation at 96 weeks
Oxygen saturation at nadir during the 6-minute walk test
Time frame: At 96 weeks
Change from baseline in modified Rodnan skin score (mRSS) at 48 weeks
Scores range from 0 to 51, with higher scores indicating more skin involvement.
Time frame: At 48 weeks
Change from baseline in modified Rodnan skin score (mRSS) at 96 weeks
Scores range from 0 to 51, with higher scores indicating more skin involvement.
Time frame: At 96 weeks
Change from baseline in nailfold capillary density at 48 weeks
Mean number of capillaries per mm
Time frame: At 48 weeks
Change from baseline in nailfold capillary density at 96 weeks
Mean number of capillaries per mm
Time frame: At 96 weeks
Change from baseline in nailfold capillaroscopy abnormalities and patterns at 48 weeks
Ectasias/megacapillaries are scored using a semi-quantitative scale (0 = no, 1 = ≤33%, 2= 33-66%, and 3 = ≥66% abnormalities/linear mm)
Time frame: At 48 weeks
Change from baseline in nailfold capillaroscopy abnormalities and patterns at 96 weeks
Ectasias/megacapillaries are scored using a semi-quantitative scale (0 = no, 1 = ≤33%, 2= 33-66%, and 3 = ≥66% abnormalities/linear mm)
Time frame: At 96 weeks
Change from baseline in quantitative SSc autoantibody titers at 48 weeks
Time frame: At 48 weeks
Change from baseline in quantitative SSc autoantibody titers at 96 weeks
Time frame: At 96 weeks
Change from baseline in Krebs von Lungen 6 (KL-6) titers at 48 weeks
Time frame: At 48 weeks
Change from baseline in Krebs von Lungen 6 (KL-6) titers at 96 weeks
Time frame: At 96 weeks
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 28 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Dec 2023 → Aug 2024, primary completion Dec 2024 → Dec 2026 and completion Dec 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mycophenolic Acid
Centre hospitalier de l'Université de Montréal (CHUM) →